Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review

Drug and Alcohol Dependence

Volumn 134, Issue 1, 2014, Pages 251-258

  Feelemyer, Jonathan P ^a   Jarlais, Don C Des ^a   Arasteh, Kamyar ^a   Phillips, Benjamin W ^a   Hagan, Holly ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Addiction severity index; Low and middle income countries; Opioid dependence; Opioid substitution treatment (OST); People who inject drugs; Quality of life (WHOQOL BREF)

Indexed keywords

BUPRENORPHINE; METHADONE;

ADDICTION SEVERITY INDEX; ARTICLE; FAMILY LIFE; FOLLOW UP; HEALTH PROGRAM; HUMAN; LOWEST INCOME GROUP; MEDICOLEGAL ASPECT; MIDDLE INCOME GROUP; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SOCIAL STATUS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION QUALITY OF LIFE BREF QUESTIONNAIRE;

ADDICTION SEVERITY INDEX; LOW AND MIDDLE INCOME COUNTRIES; OPIOID DEPENDENCE; OPIOID SUBSTITUTION TREATMENT (OST); PEOPLE WHO INJECT DRUGS; QUALITY OF LIFE (WHOQOL-BREF);

BEHAVIOR, ADDICTIVE; HUMANS; INTERNATIONALITY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POVERTY; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84890211113     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.10.011     Document Type: Article

References (61)

1. Apodaca T.R., Longabaugh R. Mechanisms of change in motivational interviewing: a review and preliminary evaluation of the evidence. Addiction 2009, 104:705-715.
2. Baharom N., Hassan M.R., Ali N., Shah S.A. Improvement of quality of life following 6 months of methadone maintenance therapy in Malaysia. Subst. Abuse Treat. Prev. Policy 2012, 7:32.
3. Bell J., Shanahan M., Mutch C., Rea F., Ryan A., Batey R., Dunlop A., Winstock A. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007, 102:1899-1907.
4. Bergner M., Bobbitt R.A., Carter W.B., Gilson B.S. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 1981, 787-805.
5. Brown L.S., Alterman A.I., Rutherford M.J., Cacciola J.S., Zaballero A.R. Addiction Severity Index scores of four racial/ethnic and gender groups of methadone maintenance patients. J. Subst. Abuse 1993, 5:269-279.
6. Bultler S.F., Budman S.H., Goldman R.J., Newman F.J., Beckley K.E., Trottier D., Cacciola J.S. Initial validation of a computer-administered Addiction Severity Index: the ASI-MV. Psychol. Addict. Behav. 2001, 15:4.
7. Caplehorn J.R., Lumley T.S., Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug Alcohol Depend. 1998, 52:57-61.
8. Chen C.Y., Ting S.Y., Tan H.K., Yang M.C. A multilevel analysis of regional and individual effects on methadone maintenance treatment in Taiwan. Value Health 2012, 15:S60-S64.
9. Crawford N.D., Ford C., Galea S., Latkin C., Jones K.C., Fuller C.M. The relationship between perceived discrimination and high-risk social ties among illicit drug users in New York City, 2006-2009. AIDS Behav. 2013, 17:419-426.
10. De Maeyer J., Vanderplasschen W., Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int. J. Drug Policy 2010, 21:364-380.
11. Deng C.F., Ma X., Zhou H., Liu Q.L., Yang Y., Song Z., Wu F. Quality of life of heroin dependent patients with methadone maintenance therapy. Sichuan Da Xue Xue Bao Yi Xue Ban 2009, 40:539-543.
12. Dole V.P., Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965, 193:646-650.
13. Donoghoe M. Prove it: a standardised approach to evaluating opioid substitution treatment in Ukraine. Proceedings of the 20th International Harm Reduction Conference 2009.
14. Dvoryak S., Grishayeva I. First experience of opioid therapy with buprenorphine in Ukraine. Heroin Addict. Relat. Clin. Probl. 2008, 10:13-18.
15. Ferri M., Davoli M., Perucci C.A. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst. Rev. 2010, CD003410.
16. Gerstein D., Johnson R., Harwood H., Fountain D., Suter N., Malloy K., Center N.O.R., America U.S., Lewin-VHI o.I. Evaluating recovery services: the California Drug and Alcohol Treatment Assessment (CALDATA); General Report. National Opinion Research Center (NORC) 1994.
17. Ghodse H., Clancy C., Oyefeso A., Rosinger C., Finkbeiner T., Schifano F., Copez C. The impact of methadone substitution therapy (MST) on illicit drug use and drug abuse-related quality of life: a european study. Heroin Addict. Relat. Clin. Probl. 2003, 5:5-16.
18. Giacomuzzi S.M., Ertl M., Kemmler G., Riemer Y., Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. Sci. World J. 2005, 5:452-468.
19. Goldman F., Berman J., Imboden J. A methadone maintenance program in a community general hospital: a first year's experience. MD State Med. J. 1973, 22:48-51.
20. Habrat B., Chmielewska K., Baran-Furga H., Keszycka B., Taracha E. Subjective quality of life in opiate-dependent patients before admission after six months and one-year participation in methadone program. Przegl Lek 2002, 59:351-354.
21. Hedrich D., Alves P., Farrell M., Stover H., Moller L., Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 2012, 107:501-517.
22. Higgins J., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.10 2011, John Wiley & Sons, Hoboken NJ, USA.
23. Hser Y.I., Li J., Jiang H., Zhang R., Du J., Zhang C., Zhang B., Evans E., Wu F., Chang Y.J., Peng C., Huang D., Stitzer M.L., Roll J., Zhao M. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction 2011, 106:1801-1809.
24. Kakko J., Svanborg K.D., Kreek M.J., Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003, 361:662-668.
25. Karow A., Verthein U., Pukrop R., Reimer J., Haasen C., Krausz M., Schafer I. Quality of life profiles and changes in the course of maintenance treatment among 1015 patients with severe opioid dependence. Subst. Use Misuse 2011, 46:705-715.
26. Korthuis P.T., Tozzi M.J., Nandi V., Fiellin D.A., Weiss L., Egan J.E., Botsko M., Acosta A., Gourevitch M.N., Hersh D., Hsu J., Boverman J., Altice F.L. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J. Acquir. Immune Defic. Syndr. 2011, 56:S39-S45.
27. Leonhard C., Mulvey K., Gastfriend D.R., Shwartz M. The Addiction Severity Index a field study of internal consistency and validity. J. Subst. Abuse Treat. 2000, 18:129-135.
28. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., GÃ̧tzsche P.C., Ioannidis J.P., Clarke M., Devereaux P., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Int. Med. 2009, 151:W-65-W-94.
29. Lua P.L., Talib N.S. A 12-month evaluation of health-related quality of life outcomes of methadone maintenance program in a rural Malaysian sample. Subst. Use Misuse 2012, 47:1100-1105.
30. Maremmani I., Pani P.P., Pacini M., Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J. Subst. Abuse Treat. 2007, 33:91-98.
31. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207.
32. McLaughlin D., Long A. An extended literature review of health professionals' perceptions of illicit drugs and their clients who use them. J. Psychiatr. Ment. Health Nurs. 1996, 3:283-288.
33. McLellan A.T. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction 2002, 97:249-252.
34. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness. JAMA 2000, 284:1689-1695.
35. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. J. Nerv. Ment. Dis. 1980, 168:26-33.
36. Moos R.H., Finney J.W., Federman E.B., Suchinsky R. Specialty mental health care improves patients' outcomes: findings from a nationwide program to monitor the quality of care for patients with substance use disorders. J. Stud. Alcohol Drugs 2000, 61:704.
37. Musa R., Abu Bakar A.Z., Ali Khan U. Two-year outcomes of methadone maintenance therapy at a clinic in Malaysia. Asia Pacific J. Public Health 2012, 24:826-832.
38. Paulus I., Halliday R. Rehabilitation and the narcotic addict: results of a comparative methadone withdrawal program. CMAJ 1967, 96:655-659.
39. Raymond H.F., McFarland W. Racial mixing and HIV risk among men who have sex with men. AIDS Behav. 2009, 13:630-637.
40. Rosen C.S., Henson B.R., Finney J.W., Moos R.H. Consistency of self-dministered and interview-based Addiction Severity Index composite scores. Addiction 2000, 95:419-425.
41. Ryan C.F., White J.M. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction 1996, 91:39-45.
42. Saxon A.J., Wells E.A., Fleming C., Jackson T.R., Calsyn D.A. Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction 1996, 91:1197-1209.
43. Schaub M., Chtenguelov V., Subata E., Weiler G., Uchtenhagen A. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. Int. J. Drug Policy 2010, 21:229-233.
44. Schaub M., Subata E., Chtenguelov V., Weiler G., Uchtenhagen A. Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes. Eur. Addict. Resource 2009, 15:157-162.
45. Solomon S., Hawcroft C., Narasimhan P., Subbaraman R., Srikrishnan A., Cecelia A., Kumar M.S., Solomon S., Gallant J., Celentano D. Comorbidities among HIV-infected injection drug users in Chennai. Indian J. Med. Res. 2008, 127:447.
46. Stark M.J., Campbell B.K. A psychoeducational approach to methadone maintenance treatment: a survey of client reactions. J. Subst. Abuse Treat. 1991, 8:125-131.
47. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and Addiction Severity Index. J. Clin. Psychopharmacol. 1996, 16:58-67.
48. Torrens M., Domingo-Salvany A., Alonso J., Castillo C., San L. Methadone and quality of life. Lancet 1999, 353:1101.
49. Tracy E.M., Laudet A.B., Min M.O., Kim H., Brown S., Jun M.K., Singer L. Prospective patterns and correlates of quality of life among women in substance abuse treatment. Drug Alcohol Depend. 2012, 124:242-249.
50. Tran B.X., Ohinmaa A., Duong A.T., Do N.T., Nguyen L.T., Nguyen Q.C., Mills S., Jacobs P., Houston S. Changes in drug use are associated with health-related quality of life improvements among methadone maintenance patients with HIV/AIDS. Qual. Life Res. 2012, 21:613-623.
51. Turner-Bowker D., DeRosa M., Ware J.E. SF-36 health survey 2008.
52. Uchtenhagen A., Ladjevic T., Rehm J. WHO Guidelines for Psychosocially Assisted Pharmacological Teatment of Persons Dependent on Opioids 2007, WHO Guidelines for Pyschosocially Assisted Pharmacotherapy of Opioid Dependence, Geneva, Switzerland.
53. Wang H., Zhou J., Huang L., Li X., Fennie K.P., Williams A.B. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. J. Clin. Nurs. 2010, 19:380-388.
54. Wang P.W., Wu H.C., Yen C.N., Yeh Y.C., Chung K.S., Chang H.C., Yen C.F. Change in quality of life and its predictors in heroin users receiving methadone maintenance treatment in Taiwan: an 18-month follow-up dtudy. Am. J. Drug Alcohol Abuse 2012, 38:213-219.
55. Ward J., Mattick R.P., Hall W. The effectiveness of methadone maintenance treatment: an overview. Drug Alcohol Rev. 1994, 13:327-336.
56. Wiklund I. The Nottingham Health Profile - a measure of health-related quality of life. Scand. J. Prim. Health Care Suppl. 1990, 1:15.
57. World Bank Country and Lending Groups by Income. World Bank Country and Lending Groups 2011, World Bank, Washington, DC.
58. World Health Organization Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual. Life Res. 1993, 2:153-159.
59. World Health Organization WHOQOL-BREF: Introduction, Administration, Scoring and Generic Version of the Assessment 1996, WHO, Geneva.
60. World Health Organization The WHO Collaborative Study on Substitution Therapy of Opioid Dependence and HIV/AIDS 2003, World Health Organization, Geneva.
61. Yin W., Hao Y., Sun X., Gong X., Li F., Li J., Rou K., Sullivan S.G., Wang C., Cao X. Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int. J. Epidemiol. 2011, 39:ii29-ii37.